1 completed, 1 recruiting, 1 unknown. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Prostate Cancer Patients: new trials by email Literature Review of Prostate Cancer Patients trials Research Report on Prostate Cancer Patients
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody - Prostate Cancer Patients, Non-castrate Prostate Cancer | Phase 1 | Recruiting | University of Wisconsin, Madison | 14 | 2026-03-03 | 2026-03-11 |
| The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680 - Prostate Cancer Patients | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2020-06-15 | 2023-02-09 |
| Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion Repaglinide, Bupropion and SHR3680 - Prostate Cancer Patients | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2020-06-01 | 2020-12-11 |
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Bupropion (1) · Midazolam (1) · Nivolumab (1) · Omeprazole (1) · Warfarin (1) · repaglinide (1) · spartalizumab (1)
Jiangsu HengRui Medicine Co., Ltd. (2) · University of Wisconsin, Madison (1)
China (2) · United States (1)
Douglas McNeel, MD, PhD (1) · Weiqing Han, Ph.D (1)